Jepsen, Cecilie Heerdegen
Novo Nordisk (Denmark)
3 papers on CoChat
Most cited papers
- Verified
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 814
- Verified
Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials
von Scholten, B. J., Davies, M. J., Persson, F., Hansen, T. W., Madsbad, S., Endahl, L., Jepsen, C. H., & Rossing, P. (2017) · Journal of Diabetes and its Complications
Chronic Kidney Disease and DiabetesDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 11
- Verified
Age no Impediment to Effective Weight Loss with Liraglutide 3.0 Mg: Data from Two Randomized Trials
Rubino, D., Coelho, R., Kahan, S., Kushner, R., Wilding, J., Jepsen, C., Smolarz, G., & Wyatt, H. (2018) · International Journal of Nutrology
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 4
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free